Published in Exp Cell Res on April 17, 2006
E-cadherin inhibits cell surface localization of the pro-migratory 5T4 oncofetal antigen in mouse embryonic stem cells. Mol Biol Cell (2007) 1.26
The function of e-cadherin in stem cell pluripotency and self-renewal. Genes (Basel) (2011) 0.92
CXCR4 mediated chemotaxis is regulated by 5T4 oncofetal glycoprotein in mouse embryonic cells. PLoS One (2010) 0.86
Potential for pharmacological manipulation of human embryonic stem cells. Br J Pharmacol (2013) 0.85
Trophoblast glycoprotein: possible candidate mediating podocyte injuries in glomerulonephritis. Am J Nephrol (2010) 0.77
Epithelial-mesenchymal transition events during human embryonic stem cell differentiation. Cancer Res (2007) 2.10
Abrogation of E-cadherin-mediated cell-cell contact in mouse embryonic stem cells results in reversible LIF-independent self-renewal. Stem Cells (2009) 1.63
Immunological responses in women with human papillomavirus type 16 (HPV-16)-associated anogenital intraepithelial neoplasia induced by heterologous prime-boost HPV-16 oncogene vaccination. Clin Cancer Res (2004) 1.51
The role of extracellular spacer regions in the optimal design of chimeric immune receptors: evaluation of four different scFvs and antigens. J Immunother (2005) 1.50
TSLC1 gene silencing in cervical cancer cell lines and cervical neoplasia. J Natl Cancer Inst (2004) 1.45
Bead-isolated human CD4+CD25+ T regulatory cells are anergic and significantly suppress proliferation of CD4+CD25- T responder cells. Clin Immunol (2006) 1.38
Frequency of regulatory T cells in renal cell carcinoma patients and investigation of correlation with survival. Cancer Immunol Immunother (2007) 1.32
E-cadherin inhibits cell surface localization of the pro-migratory 5T4 oncofetal antigen in mouse embryonic stem cells. Mol Biol Cell (2007) 1.26
Vaccination of healthy volunteers with human papillomavirus type 16 L2E7E6 fusion protein induces serum antibody that neutralizes across papillomavirus species. Cancer Res (2006) 1.26
Immunological and clinical responses in women with vulval intraepithelial neoplasia vaccinated with a vaccinia virus encoding human papillomavirus 16/18 oncoproteins. Cancer Res (2003) 1.24
Safety and immunogenicity of TA-HPV, a recombinant vaccinia virus expressing modified human papillomavirus (HPV)-16 and HPV-18 E6 and E7 genes, in women with progressive cervical cancer. Clin Cancer Res (2002) 1.22
Modulation of lymphocyte regulation for cancer therapy: a phase II trial of tremelimumab in advanced gastric and esophageal adenocarcinoma. Clin Cancer Res (2010) 1.14
The 5T4 oncofoetal antigen is an early differentiation marker of mouse ES cells and its absence is a useful means to assess pluripotency. J Cell Sci (2003) 1.14
For debate: that Australia should consider changing to the bivalent vaccine. Sex Health (2010) 1.14
Cancer vaccines and immunotherapy. Br Med Bull (2002) 1.07
The human cytomegalovirus immediate-early promoter is transcriptionally active in undifferentiated mouse embryonic stem cells. Stem Cells (2002) 1.07
Clinical and immunologic results of a phase II trial of sequential imiquimod and photodynamic therapy for vulval intraepithelial neoplasia. Clin Cancer Res (2008) 1.05
Vaccination with HPV16 L2E6E7 fusion protein in GPI-0100 adjuvant elicits protective humoral and cell-mediated immunity. Vaccine (2008) 1.05
Recommendations for cervical cancer prevention in Asia Pacific. Vaccine (2008) 1.04
Comprehensive control of human papillomavirus infections and related diseases. Vaccine (2013) 1.02
Significant variations in differentiation properties between independent mouse ES cell lines cultured under defined conditions. Exp Cell Res (2004) 0.97
5T4 interacts with TIP-2/GIPC, a PDZ protein, with implications for metastasis. Biochem Biophys Res Commun (2002) 0.96
Vaccine and antibody-directed T cell tumour immunotherapy. Biochim Biophys Acta (2004) 0.93
Attenuated recombinant vaccinia virus expressing oncofetal antigen (tumor-associated antigen) 5T4 induces active therapy of established tumors. Mol Cancer Ther (2002) 0.93
Oncofetal antigen 5T4 expression as a prognostic factor in patients with gastric cancer. Anticancer Res (2002) 0.92
Combination of vaccination and chimeric receptor expressing T cells provides improved active therapy of tumors. J Immunol (2006) 0.90
An MVA-based vaccine targeting the oncofetal antigen 5T4 in patients undergoing surgical resection of colorectal cancer liver metastases. J Immunother (2008) 0.89
Characterization of the murine 5T4 oncofoetal antigen: a target for immunotherapy in cancer. Biochem J (2002) 0.88
Use of adenoviruses encoding CD40L or IL-2 against B cell lymphoma. Int J Cancer (2004) 0.87
5T4 glycoprotein regulates the sensory input-dependent development of a specific subtype of newborn interneurons in the mouse olfactory bulb. J Neurosci (2012) 0.86
Human papillomavirus type 16 E2- and L1-specific serological and T-cell responses in women with vulval intraepithelial neoplasia. J Gen Virol (2003) 0.86
CXCR4 mediated chemotaxis is regulated by 5T4 oncofetal glycoprotein in mouse embryonic cells. PLoS One (2010) 0.86
Immunotherapy for gastrointestinal cancer: current status and strategies for improving efficacy. Expert Opin Biol Ther (2008) 0.86
Adoptive transfer of T(reg) depleted autologous T cells in advanced renal cell carcinoma. Cancer Immunol Immunother (2007) 0.85
Immune evasion mechanisms in colorectal cancer liver metastasis patients vaccinated with TroVax (MVA-5T4). Cancer Immunol Immunother (2009) 0.85
Association between human leukocyte antigen polymorphism and human papillomavirus 16-positive vulval intraepithelial neoplasia in British women. Cancer Res (2003) 0.84
Regulation of autologous immunity to the mouse 5T4 oncofoetal antigen: implications for immunotherapy. Cancer Immunol Immunother (2011) 0.84
CD8 T-cell recognition of human 5T4 oncofetal antigen. Int J Cancer (2006) 0.83
Embryonic expression of murine 5T4 oncofoetal antigen is associated with morphogenetic events at implantation and in developing epithelia. Dev Dyn (2005) 0.83
Immunization with a recombinant adenovirus encoding a lymphoma idiotype: induction of tumor-protective immunity and identification of an idiotype-specific T cell epitope. J Immunol (2002) 0.83
Herpes simplex virus VP22-human papillomavirus E2 fusion proteins produced in mammalian or bacterial cells enter mammalian cells and induce apoptotic cell death. Biotechnol Appl Biochem (2004) 0.81
5T4 as a target for immunotherapy in renal cell carcinoma. Expert Rev Anticancer Ther (2009) 0.80
CXCL12 receptor preference, signal transduction, biological response and the expression of 5T4 oncofoetal glycoprotein. J Cell Sci (2012) 0.79
Glycosylation and epitope mapping of the 5T4 glycoprotein oncofoetal antigen. Biochem J (2002) 0.79
Targeting immune effector molecules to human tumor cells through genetic delivery of 5T4-specific scFv fusion proteins. Cancer Gene Ther (2002) 0.79
CD4+ T-cell recognition of human 5T4 oncofoetal antigen: implications for initial depletion of CD25+ T cells. Cancer Immunol Immunother (2007) 0.79
Diffusible VP22-E2 protein kills bystander cells and offers a route for cervical cancer gene therapy. Hum Gene Ther (2006) 0.78
Novel vectors for homologous recombination strategies in mouse embryonic stem cells: an ES cell line expressing EGFP under control of the 5T4 promoter. Exp Cell Res (2007) 0.78
Poor prognosis associated with human papillomavirus α7 genotypes in cervical carcinoma cannot be explained by intrinsic radiosensitivity. Int J Radiat Oncol Biol Phys (2013) 0.77
Adoptive transfer of anti-idiotypic T cells cure mice of disseminated B cell lymphoma. J Immunother (2004) 0.77
The use of vaccines in the prevention and treatment of cervical cancer. Clin Oncol (R Coll Radiol) (2002) 0.77
Circulating regulatory T cells in endometrial cancer: a role for age and menopausal status. Immunol Invest (2010) 0.77
No alteration in NK function or zeta chain expression in NK and T cells of cervical cancer patients. Gynecol Oncol (2003) 0.75
Immunotherapy success in prophylaxis cannot predict therapy: prime-boost vaccination against the 5T4 oncofoetal antigen. Cancer Immunol Immunother (2006) 0.75